Merck Serono launches Ismigen vaccine in Argentina
This article was originally published in Scrip
Merck Serono has launched Ismigen in Argentina for the prophylaxis and treatment of chronic, subacute and acute respiratory tract infections. The sublingual vaccine, made up of polyvalent bacterial mechanical lysate, is licensed from Lallemand Pharma International. It is now approved for marketing in 12 countries and has been filed in a further 25 countries. A recent Phase II clinical trial of 63 subjects suggests that Ismigen provides a therapeutic benefit to chronic obstructive pulmonary disease (COPD) patients who are already being treated with salmeterol and fluticasone.